地中海贫血
中国大陆
遗传诊断
医学
疾病
造血干细胞移植
中国
重症监护医学
儿科
内科学
政治学
遗传学
生物
基因
法学
作者
Lü-Hong Xu,Jian-Pei Fang
出处
期刊:Hemoglobin
[Informa]
日期:2013-04-18
卷期号:37 (4): 307-314
被引量:11
标识
DOI:10.3109/03630269.2013.789967
摘要
β-Thalassemia (β-thal) is caused by a decrease in the production of β-globin chains that is a genetic disorder worldwide. The diagnosis of β-thal major (β-TM) depends on clinical manifestations, laboratory investigations, family history and genetic analysis. Patients with β-TM require long-term blood transfusion and chelation therapy. Hematopoietic stem cell transplantation is the only strategy for curing this disease. Many patients with β-TM cannot get regular diagnosis and treatment in developing countries. With economic improvement and medical technology development, a great progress has been made in Mainland China. In this study, we describe the current status of diagnosis and treatment of β-thal in Mainland China.
科研通智能强力驱动
Strongly Powered by AbleSci AI